TABLE.
Adjuvant Trials in Patients With Resected NSCLC*
| 5-y survival (%) |
|||||||
|---|---|---|---|---|---|---|---|
| Reference | No. of patients |
Pathologic stage |
Treatment Adherence (%) |
Adjuvant Chemotherapy group |
Observation group |
P value | Regimen |
| IALT58 | 1867 | I-III | 74 | 45 | 40 | <.03 | CDDP + ETP or + VNR or + VBL |
| Winton et al59 (NCIC JBR.10) |
482 | IB-II | 50 | 69 | 54 | .03 | CDDP + VNR |
| Douillard et al60 (ANITA) |
840 | IB-IIIA | 56 | 51 | 43 | .01 | CDDP + VNR |
| Strauss et al61 (CALGB) |
344 | IB | 85 | 60 | 57 | .32 | CBDCA + PTX |
| Xu et al62 | 70 | I-III | 91 | 49 | 31 | .05 | CDDP + CPA + VCR + DOX + UFT |
| Mineo et al63 | 66 | IB | 76 | 63 | 45 | .04 | CDDP + ETP |
| Tada et al64 (OLCS) |
95 | II-III | 49 | 38 | 37 | .54 | CDDP + VDS + UFT |
| Imaizumi et al65 (ACLC) |
150 | I | 61 | 88 | 66 | .045 | CDDP + VDS + UFT |
| Tada et al66 | 119 | IIIA | 58 | 28 | 36 | .89 | CDDP + VDS |
*
ACLC = Adjuvant Chemotherapy for Lung Cancer; ANITA = Adjuvant Navelbine International Trialist Association; CALGB = Cancer and Leukemia Group B; CBDCA = carboplatin; CDDP = cisplatin; CPA = cyclophosphamide; DOX = doxorubicin; ETP = etoposide; IALT = International Adjuvant Lung Cancer Trial; NCIC = National Cancer Institute of Canada; NSCLC = non–small-cell lung cancer; OLCS = Osaka Lung Cancer Study; PTX = paclitaxel; UFT = uracil-tegafur; VBL = vinblastine; VCR = vincristine; VDS = vindesine; VNR = vinorelbine.